Show Notes
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Selin Kurnaz, Co-Founder and CEO at Massive Bio,
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Selin, covering:
How a cancer diagnosis in her family led Selin down a path of accidental entrepreneurship, fundraising, and the application of AI in drug development. The major pivots in Massive Bio’s journey that transformed it into a broker of access between patients and pharmaceutical companies. Her views on the misallocation of capital in market access enablers versus research and development. How gaining traction with advocates inside big pharma helped ensure investors took notice. Why the influence of AI on clinical trials and real world evidence will continue to grow as part of the patient journey.
Selin Kurnaz graduated from Boğaziçi University in Turkey, where she had a dual major in industrial engineering and mechanical engineering. She then continued her education in the United States, where she obtained two masters degrees and a doctorate in mechanical engineering at the University of Michigan. Following her education, Selin served as an executive consultant on strategy, operations, and company trading for a decade. In 2015, she co-founded Massive Bio.
Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
More from Molecule to Market: Inside the outsourcing space
Live from CPHI Milan, Molecule to Market and ramarketing bring together 11 senior leaders from across the global pharma outsourcing sector to tackle some of the industry's biggest trade-offs.
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:
In this special encore episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mark Bamforth OBE, serial entrepreneur, investor and mentor to CEOs. Your host, Raman Sehgal, revisits one of Molecule to Market’s most memorable conversations, bringing together Mark’s original two-part story of building and selling three biotech CDMOs for a combined value of $2.5bn. Raman and Mark discuss the pharmaceutical and biotechnology supply chain, covering:
In this special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector through the perspective of pharma-side buyers and external manufacturing leaders. Your host, Raman Sehgal, brings together insights from Daniel Hurni, Felipe Furiati, Frank Binder, and the buyer-side panel from CDMO Live Europe: When Outsourcing Goes Wrong, covering:
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Frank Binder, Independent Consultant (external manufacturing and supply chain management).